Bioelectric Stimulation for Concussion Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for concussions lack effectiveness, as anti-inflammatory drugs like NSAIDs have failed to provide viable solutions, and existing approaches do not account for the unique inflammatory signature of concussed brains, necessitating customized and time-specific management of inflammatory responses.
Innovation Solution
A method involving bioelectric stimulation to control protein expression, delivering specific proteins such as SDF-1, IGF-1, and IL-6 at precise times to regulate inflammation, combined with stem cell therapies and bioelectric devices that monitor and adjust cytokine levels in real-time to promote recovery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If general anti-inflammatory drugs (NSAIDs) are used to treat concussion, then inflammation is reduced, but recovery is worsened due to suppression of necessary inflammatory responses
Solution Approach 1:
The patent applies local quality by delivering specific anti-inflammatory cytokines (IL-4, IL-10, TGF-beta) directly to the brain tissue through convection-enhanced delivery, rather than using systemic NSAIDs. This localized approach allows precise control of inflammation in the affected area while preserving necessary inflammatory responses elsewhere in the body.
Solution Approach 2:
The patent changes the parameter of inflammation control from non-specific suppression (NSAIDs) to specific cytokine modulation. By administering defined combinations of cytokines at controlled doses and timepoints, the treatment transforms the inflammatory profile from harmful to beneficial, promoting recovery without the side effects of general anti-inflammatory drugs.
2Loss of time
If inflammation is suppressed early after concussion, then acute damage is reduced, but long-term recovery is impaired due to disrupted healing processes
Solution Approach 1:
The patent applies preliminary action by administering IL-4 and IL-10 within 24 hours of injury to prevent excessive acute inflammation and edema. This early intervention controls initial damage while setting the stage for subsequent pro-healing cytokine administration that promotes long-term recovery processes.
Solution Approach 2:
The treatment protocol uses periodic action by administering cytokines at multiple timepoints: IL-4 and IL-10 in the first 24 hours, followed by TGF-beta at 24-48 hours, and additional doses at 72 hours and 5-7 days. This staged approach matches the temporal needs of different recovery phases, controlling acute inflammation first, then promoting healing and remodeling.
3Ease of operation
If standardized treatment protocols are used for concussion, then treatment simplicity is maintained, but individual variability in inflammatory responses is not addressed
Solution Approach 1:
The patent applies dynamics by creating an adaptable treatment protocol that can be adjusted based on individual patient response. While providing a standardized framework of cytokine administrations, the protocol allows modification of dosing intervals and additional cytokine additions (such as IFN-gamma for secondary hits) based on clinical assessment of each patient's inflammatory profile and recovery progress.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables tailored inflammation control, promoting balanced protein expression and tissue healing, potentially leading to improved recovery outcomes for concussions and traumatic brain injuries by mimicking healthy recovery processes.
Implementation Method 1
controlled protein expression on demand by bioelectric stimulation
Data Source
AI summary
Described is a low voltage, pulsed electrical stimulation device for reducing inflammation in a subject, which can be useful in the treatment of concussions, traumatic brain injury, cancer, and so forth.